Our Medicines | GileadPro

Sofosbuvir/Velpatasvir Gilead

Sofosbuvir/Velpatasvir Gilead is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older.¹

Ledipasvir/Sofosbuvir Gilead

Ledipasvir/Sofosbuvir Gilead is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above.²

Please consult the SmPC for hepatitis C virus (HCV) genotype-specific activity.

Sofosbuvir/Velpatasvir/Voxilaprevir Gilead

Sofosbuvir/Velpatasvir/Voxilaprevir Gilead is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg.³

Hepcludex®▼ (bulevirtide)

Hepcludex® is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult and paediatric patients 3 years of age and older weighing at least 10 kg with compensated liver disease.⁴

LIVDELZI®▼ (seladelpar)

LIVDELZI® has received conditional marketing authorisation for the treatment of primary biliary cholangitis, including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.⁵